NCT04694638 is a NA clinical trial of Body position change in Prone Positioning, sponsored by Mayo Clinic.

Who is sponsoring NCT04694638?

NCT04694638 is sponsored by Mayo Clinic.

What drugs are being tested in NCT04694638?

Interventions in NCT04694638: Body position change.

What condition does NCT04694638 study?

NCT04694638 studies Prone Positioning, Covid19, Hypoxemic Respiratory Failure, ARDS, Non Invasive Ventilation, High Flow Nasal Cannulla.

Is NCT04694638 still recruiting?

NCT04694638 is currently completed. Last updated 5 October 2023.

Last reviewed 2023-10-05 · How we verify

NCT04694638

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection

Completed NA Last updated 5 October 2023

What this trial tests

NA trial testing Body position change in Prone Positioning in 6 participants. Completed in 10 May 2023.

Timeline

21 May 2020

Primary endpoint
10 May 2023

10 May 2023

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	6
Start date	21 May 2020
Primary completion	10 May 2023
Estimated completion	10 May 2023
Sites	1 location across United States

Drugs / interventions tested

Body position change

Conditions studied

Prone Positioning — all drugs for Prone Positioning →
Covid19 — all drugs for Covid19 →
Hypoxemic Respiratory Failure — all drugs for Hypoxemic Respiratory Failure →
ARDS — all drugs for ARDS →

Sponsor

Mayo Clinic

Who can join

Adults 18 to 110, any sex, with Prone Positioning or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research aims to understand if prone positioning combined with high-flow nasal cannula (HFNC) or non-invasive positive pressure ventilation (NIPPV) safely reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to COVID-19 infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04694638 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 5 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04694638.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing